Biomarkers In Oncology – Access & Reimbursement – Detailed, Expanded Analysis: Biomarker-Targeted Therapies For NSCLC, Malignant Melanoma, And Colorectal Cancer (US)
Market Outlook
Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer, malignant melanoma, and colorectal cancer. While biomarker-associated therapies offer the advantage of selecting the patients most likely to respond to treatment, these therapies are premium-priced and often subject to payer restrictions. We explore the drivers and barriers to use of these agents and report on how reimbursement impacts drug selection and prescribing. We also evaluate surveyed medical oncologists’ and surveyed payers’ perceptions of emerging biomarker-driven therapies in select solid-tumor indications.
Questions Answered:
- What factors most greatly influence payers’ reimbursement decisions for biomarker-driven therapies in NSCLC, malignant melanoma, and colorectal cancer? What restrictions do they impose?
- Do access and reimbursement challenges differ by indication and/or how well established is the biomarker in each indication?
- What role do reimbursement, cost, and clinical factors play in oncologists’ decisions to prescribe biomarker-driven therapies.
- What are payer opinions of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?
- What factors influence reimbursement and access for companion biomarker tests?
Product Description:
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
Scope of Report:
- Geography: United States.
- Primary research: Survey of 101 medical oncologists in the United States and survey of 30 U.S. managed care organizations (MCO) pharmacy and medical directors (PDs/MDs).
- Key drugs covered: Keytruda, Xalkori , Zykadia, Gilotrif, Tagrisso, Portrazza, Zelboraf, Tafinlar, Cotellic, Mekinist, Avastin, Erbitux, Vectibix.
Table of contents
- Biomarkers In Oncology - Access & Reimbursement - Detailed, Expanded Analysis: Biomarker-Targeted Therapies For NSCLC, Malignant Melanoma, And Colorectal Cancer (US)
- A&R US Biomarkers in Oncology 2018
- Please Note
- Executive Summary
- Key Findings
Laura Vinuesa, D.V.M., M.Sc., is a senior business insights analyst on the Oncology team at Clarivate. She specializes in bladder cancer and head and neck cancers and in optimizing market access opportunities for new biomarker-targeted therapies in oncology. Previously, she was part of the Global Market Access Insights team, for whom she analyzed the healthcare systems and pharmaceutical markets of the EU5 and focused on evolving HTA demands, P&R processes, and stringent cost-containment strategies. She obtained her doctorate in veterinary medicine from Complutense University in Madrid and a master’s degree in clinical research and pharmaceutical medicine from EPHOS Business School in Madrid.